<a href="https://www.fiercebiotech.com/biotech/astrazeneca-restarts-300m-investment-england-merck-not-budging" hreflang="en">AstraZeneca restarts £300M investment in UK, but Merck not budging</a>
AstraZeneca has resumed a £300 million investment in the UK, including a significant construction project in Cambridge, following improvements in government drug pricing negotiations. In contrast, Merck & Co. has maintained its decision to halt investments in the UK without any updates on its previous plans.
AstraZeneca's decision to resume a £300 million investment in the UK, driven by recent favorable changes in drug pricing negotiations and international trade deals, highlights the importance of strategic government partnerships in facilitating biotech investments and advancing R&D infrastructure. This scenario underscores the potential for future growth in the UK's life sciences sector, particularly in digital-enabled drug development, and may serve as a signal for other healthtech companies considering investment in regions with evolving regulatory landscapes.